Lane 1: A549 cell lysates
Lane 2: MCF-7 cell lysates
Lane 3: Mouse placenta tissue lysates
Lane 4: Mouse lung tissue lysates
Recombinant Rabbit monoclonal primary
Recombinant PD-L1 Monoclonal Antibody (ET1701-41)
Synthetic peptide within human pd-l1 aa 200-230 (extracellular).
A549 cell lysate, MCF-7 cell lysate, mouse placenta tissue lysate, mouse lung tissue lysate, human non-small cell lung cancer tissue.
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A purified.
33 kDa (Predicted band size)
Programmed cell death 1 ligand 1
PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7-H1, CD274
Belongs to the immunoglobulin superfamily. BTN/MOG family.
Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation.
Cell membrane; Single-pass type I membrane protein; Single-pass type I membrane protein; Single-pass type I membrane protein.; [Isoform 1]: Cell membrane; Single-pass type I membrane protein; Single-pass type I membrane protein.
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10).; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).